BIT 1.79% 5.7¢ biotron limited

Merck did a Joint Venture with Ridgeback Biotherapeutics to...

  1. 499 Posts.
    lightbulb Created with Sketch. 273


    Merck did a Joint Venture with Ridgeback Biotherapeutics to release the Covid-19 treatment molnupiravir.

    Yes, they have beaten BIT to the punch so far.
    As far as I know, it is also a small molecule drug.

    There can be little excuses from MM on the commercial aspects of the business such as dealmaking .


    But the fight is far from over with covid19.
    Covid19 is going to be around for a while.
    The opportunity is still present.

    MM would do well to analyse what Ridgeback Biotherapeutics did right to secure a deal with Big Pharma!!!
    I note...
    molnupiravir is not 100% effective...and it doesn't have to be!!!

    ie.
    Did you know they tested their candidate against covid19 using ferrets?
    There was a reason for that also.
    Some of the testing was sponsored by the US government also for this drug!

    BIT need to do a JV deal with the remaining Big Pharma with their best covid19 candidates or a deal with the governments.

    They need to partner with Big Pharma or Government to take advantage of the fastracking.
    There is a huge unmet need still.

    Fortunately for BIT, there is the covid19 candidates and the BIT225 for HIV!
    With the appropriate deal, BIT would easily become a multibagger.

    The focus needs to be solely on the dealmaking with Big Pharma.

    GLA BIT holders






 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
5.7¢
Change
0.001(1.79%)
Mkt cap ! $51.43M
Open High Low Value Volume
5.7¢ 5.7¢ 5.4¢ $18.26K 325.2K

Buyers (Bids)

No. Vol. Price($)
1 15893 5.6¢
 

Sellers (Offers)

Price($) Vol. No.
5.9¢ 62000 1
View Market Depth
Last trade - 15.58pm 04/06/2024 (20 minute delay) ?
Last
5.4¢
  Change
0.001 ( 3.57 %)
Open High Low Volume
5.8¢ 5.8¢ 5.4¢ 10004
Last updated 13.25pm 04/06/2024 ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.